Revance Therapeutics Inc (RVNC) - Financial and Strategic SWOT Analysis Review

  • ID: 4278526
  • SWOT Analysis
  • 43 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • Alimera Sciences Inc
  • Zogenix Inc
  • MORE
Revance Therapeutics Inc (RVNC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Revance Therapeutics Inc (Revance Therapeutics) develops, manufactures and commercializes novel botulinum toxin products. The company’s product candidate includes RT002, an injectable formulation of botulinum toxin type for the treatment of glabellar lines, cervical dystonia, and plantar fasciitis among others. It also provides RT001, a topical gel formulation of daxibotulinumtoxinA, which is designed to eliminate the use of needles. Revance Therapeutics develops products for multiple aesthetic and therapeutic applications. The company utilizes TransMTS platform technology for the development of its products. It offers products for dermatology, neurology, musculoskeletal disorders, urology and ophthalmology. Revance Therapeutics is headquartered in Newark, California, the US.

Revance Therapeutics Inc Key Recent Developments

Nov 02, 2017: Revance Releases Third Quarter 2017 Results
Sep 06, 2017: Revance Appoints Mark Foley to its Board of Directors
Aug 03, 2017: Revance Releases Second Quarter 2017 Results
Aug 02, 2017: Revance appoints new chief commercial officer and president of Aesthetics & Therapeutics
Aug 01, 2017: Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Alimera Sciences Inc
  • Zogenix Inc
  • MORE
Section 1 - About the Company
  • Revance Therapeutics Inc - Key Facts
  • Revance Therapeutics Inc - Key Employees
  • Revance Therapeutics Inc - Key Employee Biographies
  • Revance Therapeutics Inc - Major Products and Services
  • Revance Therapeutics Inc - History
  • Revance Therapeutics Inc - Company Statement
  • Revance Therapeutics Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Revance Therapeutics Inc - Business Description
  • Revance Therapeutics Inc - Corporate Strategy
  • Revance Therapeutics Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Revance Therapeutics Inc - Strengths
  • Revance Therapeutics Inc - Weaknesses
  • Revance Therapeutics Inc - Opportunities
  • Revance Therapeutics Inc - Threats
  • Revance Therapeutics Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Revance Therapeutics Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Nov 02, 2017: Revance Releases Third Quarter 2017 Results
  • Sep 06, 2017: Revance Appoints Mark Foley to its Board of Directors
  • Sep 06, 2017: Revance Appoints Mark Foley to its Board of Directors
  • Aug 03, 2017: Revance Releases Second Quarter 2017 Results
  • Aug 02, 2017: Revance appoints new chief commercial officer and president of Aesthetics & Therapeutics
  • Aug 01, 2017: Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics
  • May 09, 2017: Revance Releases First Quarter 2017 Results
  • Feb 27, 2017: Revance Releases Fourth Quarter and Full Year 2016 Results
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Revance Therapeutics Inc, Key Facts
  • Revance Therapeutics Inc, Key Employees
  • Revance Therapeutics Inc, Key Employee Biographies
  • Revance Therapeutics Inc, Major Products and Services
  • Revance Therapeutics Inc, History
  • Revance Therapeutics Inc, Subsidiaries
  • Revance Therapeutics Inc, Key Competitors
  • Revance Therapeutics Inc, Ratios based on current share price
  • Revance Therapeutics Inc, Annual Ratios
  • Revance Therapeutics Inc, Annual Ratios
  • Revance Therapeutics Inc, Interim Ratios
  • Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Revance Therapeutics Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Revance Therapeutics Inc, Performance Chart (2012 - 2016)
  • Revance Therapeutics Inc, Ratio Charts
  • Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Alder Biopharmaceuticals Inc
  • Alimera Sciences Inc
  • Anthera Pharmaceuticals Inc
  • Zogenix Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll